GA-THE-COCA-COLA-COMPANY
10.4.2024 12:01:33 CEST | Business Wire | Press release
The Coca-Cola Company, the longest-running partner of the Olympic Games, today unveiled “Celebrate Everyday Greatness,” its theme for Paris 2024 and its global roster of athletes for Team Coca-Cola.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240410031180/en/
Coca-Cola Paris 2024 Global Roster (Photo: Business Wire)
Celebrate Everyday Greatness is designed to champion life’s everyday moments – both big and small – that create magic that builds into something great. The Coca-Cola Company is focused on helping to make Paris 2024 the most spectacular Olympic and Paralympic Games ever, with activations across a portfolio of brands that engage fans and athletes while delivering a more sustainable experience.
“The Olympic and Paralympic Games are a prime opportunity for The Coca-Cola Company and our extensive portfolio of products to connect with fans,” said Brad Ross, VP Global Sports & Entertainment Marketing and Partnerships. “We will use this global stage to showcase how greatness in everyday moments can create real magic.”
In its role as a Worldwide Partner of the Olympic and Paralympic Games and Presenting Partner of the Paris 2024 Olympic Torch Relay, The Coca-Cola Company will refresh athletes, officials and spectators with its wide product portfolio of beverages.
Team Coca-Cola Paris 2024 Global Roster
The Olympic and Paralympic Games show that magic happens when the world comes together. Team Coca-Cola includes some of the world’s greatest athletes across different sports, countries and abilities. They represent the latest generation of outstanding stories to continue the company’s nearly century-long partnership with the Olympic Games.
“The pressure to perform can be overwhelming, especially when so many people rely on you to be your best, day-in and day-out,” said global soccer star and Team Coca-Cola athlete Debinha. “This is my third time competing in the Olympic Games. This year, I've made it a point to let those around me know how much they motivate me to be great, on and off the field, every day.”
The Coca-Cola Company Sustainability at Paris 2024
The Coca-Cola Company’s ambition is to have an Olympic and Paralympic Games without waste. The company will be providing packaging options to help minimize waste and reduce carbon emissions.
Coca-Cola will also work to collect and recycle bottles to give them new life or so that they can be refilled. This includes drink and water fountains with refill options, returnable glass bottles and bottles made with recycled materials. Coca-Cola products will be transported more sustainably during last-mile delivery. Low-carbon vehicles powered by electric, biogas or hydrogen will be used to deliver products to competition site venues and the Athletes’ Village.
Additional activations, both online and on the ground, throughout Paris 2024 will unite consumers in celebrating the magic of the Olympic and Paralympic Games. For more information on The Coca-Cola Company’s Paris 2024 activities, visit coca-colacompany.com.
Team Coca-Cola Roster:
Alberto Abarza (Chile, Swimming), Ellie Carpenter (Australia, Football), Linda Motlhalo (South Africa, Football), Alex Greenwood (England, Football), Emma Twigg (New Zealand, Rowing), Katie Bowen (New Zealand, Football), Lydia Williams (Australia, Football), Alex Morgan (U.S., Football), Florian Jouanny (France, Para Cycling), Mathilde Gros (France, Track Cycling), Alyssa Naehar (U.S., Football), Harrie Lavreysen (Netherlands, Cycling), Ramesh Budihal (India, Surfing), Athing Mu (U.S., Track & Field), Huynh Nhu (Vietnam, Football), Sarina Bolden (Philippines, Football), CJ Bott (New Zealand, Football), Ji So-Yun (South Korea, Football), Sean McColl (Canada, Sport Climbing), Daniel Smrokowski (U.S., Basketball), Kadeena Cox (U.K., Para Cycling & Para Athletics), Tyler Wright (Australia, Surfing), Debinha (Brazil, Football), Kadeisha Buchanan (Canada, Football), Wu Hai Yan (China, Football), Dimitrij Ovtcharov (Germany, Table Tennis)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240410031180/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom